老年人大手术后围术期加巴喷丁使用与院内不良临床事件
该回顾性队列研究利用Premier医疗数据库,纳入2009年1月1日至2018年3月31日美国医院收治的65岁以上、入院7天内接受大手术且术前未用加巴喷丁的患者967 547例,其中围术期加巴喷丁使用率12.3%(119 087例)。经1:1倾向评分匹配后纳入237 872例(118 936对),加巴喷丁组较未用组谵妄风险升高(3.4% vs 2.6%;RR 1.28,95%CI 1.23-1.34;RD 0.75/100人,95%CI 0.61-0.89),新发抗精神病药使用(0.8% vs 0.7%;RR 1.17,95%CI 1.07-1.29)和肺炎(1.3% vs 1.2%;RR 1.11,95%CI 1.03-1.20)风险亦升高,院内死亡无差异(0.3% vs 0.2%;RR 1.02,95%CI 0.88-1.18)。作者认为,为围术期疼痛管理开具加巴喷丁前应仔细评估风险获益。
要点
- 匹配队列中加巴喷丁组谵妄3.4% vs 未用组2.6%,RR 1.28(95%CI 1.23-1.34),RD 0.75/100人(95%CI 0.61-0.89)。
- 新发抗精神病药使用0.8% vs 0.7%,RR 1.17(95%CI 1.07-1.29);肺炎1.3% vs 1.2%,RR 1.11(95%CI 1.03-1.20)。
- 院内死亡0.3% vs 0.2%,RR 1.02(95%CI 0.88-1.18),两组无差异。
- 高合并症负担(合并症指数≥4 vs <4)者谵妄风险更高:RR 1.40(95%CI 1.30-1.51)vs 1.20(95%CI 1.13-1.27)。
- 合并慢性肾病者谵妄风险更高:RR 1.38(95%CI 1.27-1.49)vs 无肾病1.26(95%CI 1.19-1.33)。
适用人群与场景
- 年龄≥65岁、入院7天内接受大手术、术前未使用加巴喷丁的美国医院患者(Premier医疗数据库,2009年1月1日至2018年3月31日)。
研究设计与关键结果
- 回顾性队列研究,使用Premier医疗数据库;匹配前967 547例(平均[SD]年龄76.2[7.4]岁;女性59.6%),围术期加巴喷丁使用率12.3%(119 087例)。
- 1:1倾向评分匹配后237 872例(118 936对;平均[SD]年龄74.5[6.7]岁;女性62.7%)。
- 主要终点谵妄(诊断编码识别):加巴喷丁组4040例(3.4%)vs 未用组3148例(2.6%);RR 1.28(95%CI 1.23-1.34);RD 0.75/100人(95%CI 0.61-0.89)。
- 次要终点新发抗精神病药使用:944例(0.8%)vs 805例(0.7%);RR 1.17(95%CI 1.07-1.29);RD 0.12/100人(95%CI 0.05-0.19)。
- 次要终点肺炎:1521例(1.3%)vs 1368例(1.2%);RR 1.11(95%CI 1.03-1.20);RD 0.13/100人(95%CI 0.04-0.22)。
- 次要终点院内死亡:362例(0.3%)vs 354例(0.2%);RR 1.02(95%CI 0.88-1.18);RD 0.00/100人(95%CI -0.04至0.05)。
- 亚组:合并症指数<4 vs ≥4的谵妄RR 1.20(95%CI 1.13-1.27)vs 1.40(95%CI 1.30-1.51);RD 0.41(95%CI 0.28-0.53)vs 2.66(95%CI 2.08-3.24)/100人。
- 亚组:无慢性肾病 vs 有慢性肾病的谵妄RR 1.26(95%CI 1.19-1.33)vs 1.38(95%CI 1.27-1.49);RD 0.56(95%CI 0.42-0.69)vs 1.97(95%CI 1.49-2.46)/100人。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些结果提示为老年大手术患者围术期疼痛管理开具加巴喷丁前应仔细评估风险获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Gabapentin has been increasingly used as part of a multimodal analgesia regimen to reduce opioid use in perioperative pain management. However, the safety of perioperative gabapentin use among older patients remains uncertain.
OBJECTIVE: To examine in-hospital adverse clinical events associated with perioperative gabapentin use among older patients undergoing major surgery.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study using data from the Premier Healthcare Database included patients aged 65 years or older who underwent major surgery at US hospitals within 7 days of hospital admission from January 1, 2009, to March 31, 2018, and did not use gabapentin before surgery. Data were analyzed from June 14, 2021, to May 23, 2022.
EXPOSURES: Gabapentin use within 2 days after surgery.
MAIN OUTCOMES AND MEASURES: The primary outcome was delirium, identified using diagnosis codes, and secondary outcomes were new antipsychotic use, pneumonia, and in-hospital death between postoperative day 3 and hospital discharge. To reduce confounding, 1:1 propensity score matching was performed. Risk ratios (RRs) and risk differences (RDs) with 95% CIs were estimated.
RESULTS: Among 967 547 patients before propensity score matching (mean [SD] age, 76.2 [7.4] years; 59.6% female), the rate of perioperative gabapentin use was 12.3% (119 087 patients). After propensity score matching, 237 872 (118 936 pairs) gabapentin users and nonusers (mean [SD] age, 74.5 [6.7] years; 62.7% female) were identified. Compared with nonusers, gabapentin users had increased risk of delirium (4040 [3.4%] vs 3148 [2.6%]; RR, 1.28 [95% CI, 1.23-1.34]; RD, 0.75 [95% CI, 0.75 [0.61-0.89] per 100 persons), new antipsychotic use (944 [0.8%] vs 805 [0.7%]; RR, 1.17 [95% CI, 1.07-1.29]; RD, 0.12 [95% CI, 0.05-0.19] per 100 persons), and pneumonia (1521 [1.3%] vs 1368 [1.2%]; RR, 1.11 [95% CI, 1.03-1.20]; RD, 0.13 [95% CI, 0.04-0.22] per 100 persons), but there was no difference in in-hospital death (362 [0.3%] vs 354 [0.2%]; RR, 1.02 [95% CI, 0.88-1.18]; RD, 0.00 [95% CI, -0.04 to 0.05] per 100 persons). Risk of delirium among gabapentin users was greater in subgroups with high comorbidity burden than in those with low comorbidity burden (combined comorbidity index <4 vs ≥4: RR, 1.20 [95% CI, 1.13-1.27] vs 1.40 [95% CI, 1.30-1.51]; RD, 0.41 [95% CI, 0.28-0.53] vs 2.66 [95% CI, 2.08-3.24] per 100 persons) and chronic kidney disease (absence vs presence: RR, 1.26 [95% CI, 1.19-1.33] vs 1.38 [95% CI, 1.27-1.49]; RD, 0.56 [95% CI, 0.42-0.69] vs 1.97 [95% CI, 1.49-2.46] per 100 persons).
CONCLUSION AND RELEVANCE: In this cohort study, perioperative gabapentin use was associated with increased risk of delirium, new antipsychotic use, and pneumonia among older patients after major surgery. These results suggest careful risk-benefit assessment before prescribing gabapentin for perioperative pain management.
参考来源
- Park CM, Inouye SK, Marcantonio ER, et al. Perioperative Gabapentin Use and In-Hospital Adverse Clinical Events Among Older Adults After Major Surgery. JAMA Intern Med. 2022. PMID: 36121671. doi:10.1001/jamainternmed.2022.3680
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。